Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biologics Help Wyeth, Schering Blunt The Pain Of Tough U.S. Market

Executive Summary

Strong sales of biologics and global diversification buttressed both Wyeth and Schering-Plough - at least partially - against a tough U.S. operating environment in the third quarter and first nine months of 2008

You may also be interested in...



Schering Plough’s Bridion Faces FDA Setback

Safety concerns render anesthesia injection “not approvable” in U.S.

Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles

Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others

Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Pharma companies are bullish about biologics, seeing them as at least a partial solution for the pipeline troubles and reimbursement challenges bedeviling the industry. The major question is how best to bring these new biologics capabilities in-house--either piecemeal through a series of smaller acquisitions and licensing deals or in one fell swoop through the acquisition of a player with soup-to-nuts capabilities. Both strategies require delicate post-merger management skills, but many feel acquiring an end-to-end player is a faster, less risky solution to filling the biologics gap. But because few end-to-end biologics players are left for acquisition, in the future it seems likely that Big Pharma will be forced to make a serial acquisition strategy work.

Latest News
See All
UsernamePublicRestriction

Register

PS050255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel